No abstract

Background: Gastric cancer represents the fifth most common tumor and the thirdleading cause of cancer-related death worldwide. The results of surgical treatment of locally advanced gastric cancer remain generally poor due to the high rate of relapse after surgery. In the last decade, neoadjuvant chemotherapy has become the standard of care for patients with stage IB resectable advanced gastric cancer. The benefit in progression-free and overall survival was confirmed by several randomised trials and meta-analyses compared to immediate surgery. However, data in the "reallife" setting are rare. We conducted a retrospective study to clarify the question of whether this benefit is achievable under real-life conditions.Methods: Our retrospective study concerned patients with histologically-confirmed advanced gastric cancer clinical stage II-IIIc according to UICC (8th edition) treated at the University Hospital of Marrakech between January 2017 and December 2018. They received 2-4 cycles/3 weeks of neoadjuvant chemotherapy based on FLOT, FOLFOX, XELOX, EOX or 5FU-Cisplatin protocols.Results: 48 patients with a median age of 56 years were diagnosed with advanced gastric cancer. 67% of them are male were. Only 16 patients (33,3%) had received neoadjuvant chemotherapy and 19 were operated immediately (39,5%). Protocols used in perioperative were FLOT in 8 patients (50%) and FOLFOX in 4 patients (25%). The rest have received either EOX (1 patient), XELOX (2 patients) or 5FU-cisplatin (1 patient). 7 patients (43,75%) received 4 cycles of neoadjuvant chemotherapy. Side effects were represented by mycosis grade 2 in 2 patients, neutropenia grade 2 in 4 patients and only one patient had grade 3 toxicity. After neoadjuvant chemotherapy, we observed 3 cases of partial response and 4 of stable disease. 5 patients (31,25%) underwent surgery (R0 in all cases) by total gastrectomy and D2 lymphadenectomy. 68,42% of the group who did not receive neoadjuvant chemotherapy, were treated by concomitant chemoradiotherapy. The median overall survival in the neoadjuvant group was 21 months compared to only 12 in the second group. Conclusion:Despite the small number of patients treated, our analysis showed that selected patients with locally advanced adenocarcinoma can be safely managed with perioperative chemotherapy in daily clinical practice and our results confirm the survival benefit of perioperative treatment. abstracts Annals of Oncology Volume 31 -Issue S3 -2020 S191

from files of patients included 196 patients (male 101 patients and female 95 patients), the patients were arranged into two groups: group I included 96 patients received 5-FU concomitant with radiotherapy and group II included 103 patients received capecitabine concomitant with radiotherapy. The evaluated side effects were: anemia, neutropenia, thrombocytopenia, hepatotoxicity, renal impairment, cardiotoxicity, neurotoxicity, diarrhea, emesis, mucositis, alterations in taste, xerostomia, gingival bleeding, hypersensitivity reactions, pigmentary changes, alopecia, nail disorders, acral erythema. The collected data was revised, coded, tabulated and introduced to PC using statistical package for social science (SPSS 20.0 for windows; SPSS Inc, Chicago, IL, 2001). Suitable analysis was done according to the type of data obtained for each parameter. Results: The evaluated toxicities showed that there was a statistical significant difference with increase in number of patients who suffered from hypersensitivity reactions (p < 0.009) and alopecia (p < 0.005) in the group who received 5-Fu compared to Capecitabine group, while acral erythema was higher in the Capecitabine group (p < 0.001). The remaining toxicities were not statistical significantly higher in either groups. Conclusion: Capecitabine and 5-flurouracil have comparable toxicity profile but capecitabine offers the feasibility of being oral drug.P À 312 Role of consolidative radiation therapy after surgery in patients with stage IV rectal cancer l Hospital and Research Centre, Peshawar, Pakistan y (RT) and surgery are known to effectively palliate many ts with metastatic rectal cancer (mRC). However, whether RT survival benefit to mRC after surgery remains unclear.Program (SEER) database. Patient demographics between the RT were compared using Pearson Chi-Square tests. Propensity score and Cox proportional hazards regression analyses were performed to power of variables on cause-specific survival (CSS). of 5520 mRC patients who have received surgery were identified in SEER variable Cox regression analyses showed that RT was a protective factor of fter surgery in mRC patients (hazard ratio [HR] ¼ 0.654, 95% confidence 0.607-0.704, p < 0.001). PS matching produced 3887 mRC patients and regression analyses indicated that RT was associated with a significant f CSS in mRC patients after surgery (HR ¼ 0.455, 95%CI¼0.422-0.491).SEER database, we have identified that RT was associated with a sigadvantage in the setting of mRC patients after surgery. This study the use of RT after surgery for patients with mRC. In order to accurole of RT in the comprehensive treatment for mRC patients, more are clearly needed to be conducted.rd hypofraction radiotherapy in neoadjuvant chemotherapy of locally advanced rectal cancer v

No abstract

No abstract